This promotional meeting is intended for UK/IE healthcare professionals only and is organised and funded by LEO Pharma. LEO Pharma medicines will be discussed at this meeting.

Prescribing information and adverse event reporting for Enstilar® cutaneous foam (calcipotriol/betamethasone dipropionate) can be found below

Dermatoscopy Series 2

  • Wednesday 9th November 2022 Signs of BCC
  • Wednesday 16th November Signs of Malignancy Part 1
  • Wednesday 23rd November Signs of Malignancy Part 2
  • Wednesday 7th December Signs of Malignancy Part 3
  • Wednesday 14th December 2022 Keratotic Cancers

Promotional section of the meeting

Time Item Speaker
19:00-19:10 Welcome, introduction and promotional presentation on Enstilar® for the topical treatment of psoriasis vulgaris (plaque psoriasis) in adults. Katie Wright, Dermatology Account Manager, LEO Pharma

Enstilar® is not indicated for the treatment of skin lesions.
Enstilar® is indicated for topical treatment of psoriasis vulgaris (plaque psoriasis) in adults only.

 

Non-Promotional section of the meeting

Time Item Speaker
19:15-20:15 Dermatoscopy: Series 2 Dr George Moncrieff
20:15-20:30 Questions and Close